Lifibrol and its use
AssigneeKlinge Pharma GmbH
InventorsArtur Burger, Anita Lettenbichler, Fritz Stanislaus, Arnim Laicher, Karl Schwitzer, Axel Woschina
Life of this patent
Estimating the term…
Abstract
A new modification of Lifibrol is described with a melting point of 132.degree. C.-138.degree. C. particularly from 134.degree. C.-136.degree. C. and a primary peak in an IR spectrum at a wave number of 3,200-3,400, preferably 3,250-3,350. The new modification of Lifibrol (modification II) is distinguished in that it allows for good crystallization and, therefore, can be formulated without problems on a large industrial scale for tablets of acceptable size and high stability.
Claims12
A modification of Lifibrol (modification II) with a melting point from 132.degree. C. to 138.degree. C. and primary peak in IR-spectra at a wave number from 3200 to 3400 cm.sup.-1.
A method for the production of a well crystallized modification of Lifibrol (modification II) with a melting point from 132.degree. C. to 138.degree. C. and a primary peak in IR-spectra at a wave number from 3200 to 3400 cm.sup.-1 wherein said modification is obtainable by stirring of suspended Lifibrol of an adherent consistency (modification I) in water, methanol, ethanol, a higher alcohol, toluene, a water-ethanol mixture, or a water-methanol mixture or by crystallization from methanol, ethanol, a higher alcohol, toluene, or ethyl acetate, or by precipitation from an aqueous solution of said alcohols.
Dependencies are inferred from the claim text.